EMA Heeds Ombudsman’s Advice On Avoiding Perception Of Bias In Drug Evaluations
Changes Are In Response To An Inquiry By EU Ombudsman
Executive Summary
An inquiry by the EU Ombudsman has prompted the European Medicines Agency to introduce changes to ensure that its experts, who advise companies in the premarket phase, are not appointed to evaluate marketing applications for the same drugs.